LEVOCaBASTINE and azelastine are currently the only antihistamines available as nasal sprays for the topical therapy of seasonal allergic rhinitis. The present study was undertaken to compare the onset of action, efficacy and tolerability of these two agents in a total of 242 patients with th/s condition. This was an international, multicentre, open-label, randomized, parallel-group trial with 123 patients treated with levocabastine (0.5 mg/ml, two puffs per nostril twice daily) and 119 with azelastine (1 mg/ml, one puff per nostril twice daily). Onset of action was comparable for the two drugs with over 50% of patients in each group reporting significant symptomatic relief within 30 min of administration of the first dose of study medication. Therapeutic efficacy was also found to be comparable in the two groups with no statistically significant intergroup differences reported for any of the parameters evaluated, although assessments of global therapeutic efficacy revealed a trend favouring levocabastine.
Introduction
In recent years there has been renewed interest in the topical treatment of allergic rhinoconjunctivitis. A topical agent may be expected to have a number of advantages over an orally administered drug including a more rapid onset of action, since the active agent is administered directly to the affected site, and a reduced potential for unwanted systemic reactions. To date, only two antihistamines are available for the topical treatment of seasonal allergic rhinitis, levocabastine and azelastine.
Levocabastine has been specifically developed for topical use, and is available as both eye drops and nasal spray. In vitro studies have demonstrated that it is the most potent antihistamine available to date, 2 being 1000 times more potent than azelastine in the compound 48/80 lethality test in rats. Comparative clinical trials have shown topically applied levocabastine to be well tolerated and at least as effective as the oral antihistamines terfenadine and loratadine for the treatment ofseasonal allergic rhinoconjunctivitis,4-7 with statistically significant differences in favour of the topical drug observed in some studies. 4'5 In contrast, azelastine has p_rimarily been developed as an anti-asthma agent, 8 and is only available as a nasal spray. In addition to its antihistaminic activity, this agent appears to have other anti-allergic properties which may be of clinical benefit to patients with allergic rhinitis. In clinical trials, intranasal azelastine has been shown to be as effective as oral terfenadine, astemizole and loratadine for the treatment of patients with this allergic disorder. 9' As no direct comparison of these two topical antihistamines has been undertaken to date, the present study was initiated to compare the efficacy, onset of action and tolerability of levocabastine and azelastine nasal sprays in patients with seasonal allergic rhinitis. The study was open-label, rather than blinded, as with a nasal spray the design of the delivery device may influence therapeutic efficacy. Furthermore, the levocabastine and azelastine nasal sprays (C) Table 2 . Adverse experiences resulting in withdrawal included dry throat (levocabastine), cough (azelastine) and dyspnoea with wheezing (azelastine). As shown in Table 3 , baseline symptom severity was generally comparable in the two treatment groups, although total symptom severity was found to be 7% higher in the azelastine treatment group than in the group which received levocabastine at the start of the trial (0.05 < p < 0.1).
Pollen concentrations were considered sufficient to elicit symptoms of seasonal allergic rhinitis in both countries throughout the trial period with high counts recorded on 79% of study days.
Assessments of global therapeutic efficacy were found to favour levocabastine, however intergroup differences did not attain statistical significance. At the end of the trial, the investigator rated therapeutic efficacy as excellent or good in 70% of levocabastine-treated patients compared with 63% of those who received azelastine (Fig. 1) . The corresponding values for the patients' assessments were 68% and 61% in the two groups, respectively.
Both the investigators' and patients' assessments revealed that levocabastine and azelastine provided comparable reduction of symptom scores for sneezing, rhinorrhoea, nasal itching, nasal congestion and concurrent ocular symptoms, as well as total symptom severity (Table 3 The results of this study suggest that levocabastine and azelastine nasal sprays have comparable efficacy in patients with seasonal allergic rhinitis with both agents providing rapid, effective and sustained symptomatic relief. Although both the investigators' and the patients' assessments of global therapeutic efficacy revealed a trend in favour of levocabastine, no statistically significant intergroup differences were seen for any of the efficacy parameters evaluated. This is in keeping with the results of previous studies which have shown that these two topical antihistamines are at least as effective as oral Hreceptor antagonists for the treatment of this common condition. 4-r'9 The effects of levocabastine and azelastine were comparable on all symptoms of allergic rhi- In this trial, levocabastine nasal spray was clearly better tolerated with the overall incidence of adverse experiences markedly higher in azelastine-treated patients than in those who received levocabastine (19% versus 11%; p 0.06). As might be expected from the route of drug administration, application site reactions and taste disturbances were the most frequent adverse events occurring during the course of the trial. However, the incidence of these reactions was found to be significantly greater in patients on azelastine than with levocabastine (5% versus 1% for application site reactions; p 0.05 and 5% versus 0% for taste disturbances; p 0.01, respectively).
Topical antihistamines such as levocabastine and azelastine represent a significant advance in antihistamine research and provide a useful alternative to oral antihistamines as a therapeutic option for the treatment of patients with allergic rhinitis. Results of this initial comparative study suggest that the two agents have similar therapeutic efficacy, but that levocabastine nasal spray is better tolerated. Coupled with the fact that this agent is also available as eye drops for the relief of concurrent ocular symptoms, these findings suggest that levocabastine may be the preferred topical antihistamine for the treatment of allergic rhinoconjunctivitis.
